G1 Therapeutics Inc. announced positive topline data showing multi-lineage myelopreservation benefits in its randomized, double-blind, placebo-controlled phase II trial evaluating trilaciclib in combination with topotecan as a treatment for 2nd-/3rd-line small cell lung cancer (2/3L SCLC).
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
